China
Updated
Reviewed by Vidhi Upadhyay
China Novel Antibiotics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Infection, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
China · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
China (this report) at $747.7 Mn.
India at 8.1% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$615.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $699.4 Mn | — | — |
| 2025 (base) | $747.7 Mn | +$48.3 Mn | — |
| 2026 (forecast) | $799.3 Mn | +$51.6 Mn | +6.9% |
| 2027 (forecast) | $854.5 Mn | +$55.2 Mn | +14.3% |
| 2028 (forecast) | $913.4 Mn | +$59.0 Mn | +22.2% |
| 2029 (forecast) | $976.4 Mn | +$63.0 Mn | +30.6% |
| 2030 (forecast) | $1.04 Bn | +$67.4 Mn | +39.6% |
| 2031 (forecast) | $1.12 Bn | +$72.0 Mn | +49.2% |
| 2032 (forecast) | $1.19 Bn | +$77.0 Mn | +59.5% |
| 2033 (forecast) | $1.28 Bn | +$82.3 Mn | +70.5% |
| 2034 (forecast) | $1.36 Bn | +$88.0 Mn | +82.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$2.99 Bn
China (this report)
$747.7 Mn
Canada
$574.3 Mn
Japan
$512.4 Mn
Germany
$261.7 Mn
France
$244.3 Mn
UK
$209.3 Mn
Italy
$205.6 Mn
Brazil
$198.3 Mn
India
$179.6 Mn
Ecuador
$155.9 Mn
Spain
$144.1 Mn
Saudi Arabia
$132.4 Mn
Mexico
$109.2 Mn
Australia
$99.1 Mn
Russia
$92.2 Mn
New Zealand
$85.1 Mn
South Africa
$47.6 Mn
UAE
$41.7 Mn
Egypt
$20.5 Mn
Philippines
$18.6 Mn
Malaysia
$13.9 Mn
Hong Kong
$14.0 Mn
Singapore
$11.3 Mn
Thailand
$11.2 Mn
Kenya
$6.3 Mn
| Market size, 2025 | $747.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.36 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 6.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, infection and end user (see all) |
| Key players | Pfizer Inc., Shionogi, Merck & Co., Inc., Innoviva Specialty Therapeutics, Venatorx Pharmaceuticals (see all) |
| Regulator in China | NMPASource: National Medical Products Administration. Checked 14 Nov 2026. |
| Active clinical trials | 8 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Novel antibiotics are new antibacterial drugs designed to treat infections caused by bacteria resistant to existing medicines.
Key segments of the novel Antibiotics market include drug class (Beta-Lactam Combinations, Novel Classes and Antibody Therapies) and infection (Gram-Negative, Gram-Positive and C. difficile).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the novel Antibiotics market.
New vaccines, rapid tests and public-private funding for neglected diseases give the novel Antibiotics market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the novel Antibiotics market.
The novel Antibiotics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Drugs need approval from the National Medical Products Administration (NMPA) before sale.[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.[2] ClinicalTrials.gov lists 8 studies on Novel Antibiotics that are recruiting, active or about to start in China.[3]
[1] National Medical Products Administration. Checked 14 Nov 2026.
[2] National Healthcare Security Administration. Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for novel Antibiotics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.
What doctors and scientists are doing in Novel Antibiotics right now, from free public sources.
8 active trials in China
Recruiting, about to start, or running now.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
China · 1 shared keyword
China
China
China
China
China
Medical Devices · China
Medical Devices · China
OTC & Nutraceuticals · China
OTC & Nutraceuticals · China
Medical Devices · China
Healthcare Services · China